EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo

Yoji Tsugawa iD, Kentaro Furukawa, Tomoko Ise, Masahiro Takayama, Takeshi Ota, Takayuki Kuroda, Shinya Shano, Takashi Hashimoto, Haruyo Konishi, Takeshi Ishihara, Masaaki Sato, Haruhiko Kamada iD und 5 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0300297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Yoji Tsugawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Shionogi Pharmaceutical Research Center, Osaka, Japan. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, Antibodies, Viral, COVID-19. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The SARS-CoV-2 pandemic alerted the potential for significant harm due to future cross-species transmission of various animal coronaviruses to human. There is a significant need of antibody-based drugs to treat patients infected with previously unseen coronaviruses. In this study, we generated CV804, an antibody that binds to the S2 domain of SARS-CoV-2 spike protein, which is highly conserved across the coronavirus family and less susceptible to mutations. CV804 demonstrated broad cross-reactivities not only disease-associated human beta coronaviruses including SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-HKU1 and with existing mutant strains of SARS-CoV-2 and but also with 20 representative animal-origin coronaviruses. CV804 exhibits strong antibody-dependent cellular cytotoxicity (ADCC) to SARS-CoV-2 spike protein expressed on cells in vitro , while completely lacks virus-neutralization activity. In animal models, CV804 suppressed disease progression caused by SARS-CoV-2 infection. Structural studies using HDX-MS combined with reactivity analysis with point mutants of recombinant spike proteins revealed that CV804 binds to a unique conformational epitope within the S2 domain of the spike proteins that is highly conserved among various coronaviruses. Overall, obtained data suggest that the non-neutralizing CV804 antibody recognizes the conformational structure of the spike protein displayed on the surface of infected cells and weakens the viral virulence by supporting the host immune cells’ attack through ADCC activity in vivo . The CV804 epitope information revealed in this study is useful for designing pan-corona antibody therapeutics and universal coronavirus vaccines for preparing potential future pandemics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2Antibodies, ViralCOVID-19HumansAnimalsMiceCross ReactionsAntibody-Dependent Cell CytotoxicityAntibodies, NeutralizingMice, Inbred BALB CAntibodies, MonoclonalFemaleChlorocebus aethiopsVero Cells

Substanzen

Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Antibodies, ViralAntibodies, NeutralizingAntibodies, Monoclonal

Autor:innen und Institutionen

  • Shionogi Pharmaceutical Research Center, Osaka, Japan.
  • Laboratory of Antibody Design, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • Shionogi TechnoAdvance Research, Co., Ltd., Osaka, Japan.

ORCID-Profile: Yoji Tsugawa, Haruhiko Kamada, Satoshi Nagata

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Tsugawa, Y., Furukawa, K., Ise, T., Takayama, M., Ota, T., Kuroda, T., Shano, S., Hashimoto, T., Konishi, H., Ishihara, T., Sato, M., Kamada, H., Fukao, K., Shishido, T., Yoshikawa, M., Takahashi, T., & Nagata, S. (2024). Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo. PLOS ONE. https://doi.org/10.1371/journal.pone.0300297

Vancouver

Tsugawa Y, Furukawa K, Ise T, Takayama M, Ota T, Kuroda T, et al. Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo. PLOS ONE. 2024. doi:10.1371/journal.pone.0300297

BibTeX
@article{Tsugawa2024,
  author = {Tsugawa, Yoji and Furukawa, Kentaro and Ise, Tomoko and Takayama, Masahiro and Ota, Takeshi and Kuroda, Takayuki and Shano, Shinya and Hashimoto, Takashi and Konishi, Haruyo and Ishihara, Takeshi and Sato, Masaaki and Kamada, Haruhiko and Fukao, Keita and Shishido, Takao and Yoshikawa, Mai and Takahashi, Tatsuya and Nagata, Satoshi},
  title = {Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0300297}
}
Kostenlos starten →